4//SEC Filing
JANKOWSKI JESS 4
Accession 0001209191-23-048252
CIK 0000883107other
Filed
Sep 4, 8:00 PM ET
Accepted
Sep 5, 8:00 PM ET
Size
33.9 KB
Accession
0001209191-23-048252
Insider Transaction Report
Form 4
JANKOWSKI JESS
President, CEO, VP, CFO
Transactions
- Exercise/Conversion
Common Stock
2023-08-31$0.52/sh+2,500$1,300→ 61,500 total - Sale
Common Stock
2023-08-31$1.00/sh−2,500$2,500→ 59,000 total - Exercise/Conversion
Common Stock
2023-09-01$0.52/sh+2,500$1,300→ 61,500 total - Exercise/Conversion
Common Stock (right to purchase)
2023-09-05$0.52/sh−2,500$1,300→ 73,450 totalExercise: $0.52From: 2015-02-13Exp: 2024-02-13→ Common Stock (75,950 underlying) - Sale
Common Stock
2023-09-01$1.00/sh−2,500$2,500→ 59,000 total - Exercise/Conversion
Common Stock
2023-09-05$0.52/sh+2,500$1,300→ 61,500 total - Sale
Common Stock
2023-09-05$1.01/sh−2,500$2,535→ 59,000 total - Exercise/Conversion
Common Stock (right to purchase)
2023-08-31$0.52/sh−2,500$1,300→ 78,450 totalExercise: $0.52From: 2015-02-13Exp: 2024-02-13→ Common Stock (80,950 underlying) - Exercise/Conversion
Common Stock (right to purchase)
2023-09-01$0.52/sh−2,500$1,300→ 75,950 totalExercise: $0.52From: 2015-02-13Exp: 2024-02-13→ Common Stock (78,450 underlying)
Holdings
- 90,000
Common Stock (right to purchase)
Exercise: $4.17From: 2022-12-28Exp: 2028-12-28→ Common Stock (90,000 underlying) - 1,000(indirect: By Spouse)
Common Stock
- 59,000
Common Stock
- 69,000
Common Stock (right to purchase)
Exercise: $0.42From: 2017-02-23Exp: 2026-02-23→ Common Stock (69,000 underlying) - 81,000
Common Stock (right to purchase)
Exercise: $0.44From: 2016-02-18Exp: 2025-02-18→ Common Stock (81,000 underlying) - 81,000
Common Stock (right to purchase)
Exercise: $0.68From: 2018-02-21Exp: 2027-02-21→ Common Stock (81,000 underlying) - 90,000
Common Stock (right to purchase)
Exercise: $0.45From: 2021-06-18Exp: 2027-06-18→ Common Stock (90,000 underlying) - 72,000
Common Stock (right to purchase)
Exercise: $1.17From: 2023-12-20Exp: 2029-12-20→ Common Stock (72,000 underlying) - 90,000
Common Stock (right to purchase)
Exercise: $0.82From: 2019-05-23Exp: 2028-05-23→ Common Stock (90,000 underlying) - 16,500
Common Stock (right to purchase)
Exercise: $0.51From: 2020-05-22Exp: 2029-05-22→ Common Stock (16,500 underlying)
Footnotes (6)
- [F1]These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
- [F2]If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders.
- [F3]These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
- [F4]Subject to certain restrictions, beginning on this date, options vest in three equal installments.
- [F5]Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
- [F6]Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Documents
Issuer
NANOPHASE TECHNOLOGIES Corp
CIK 0000883107
Entity typeother
Related Parties
1- filerCIK 0001184478
Filing Metadata
- Form type
- 4
- Filed
- Sep 4, 8:00 PM ET
- Accepted
- Sep 5, 8:00 PM ET
- Size
- 33.9 KB